2020
Solanezumab in‐depth outcomes
Farlow M, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Salloway S, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Andersen S, Holdridge K, Mintun M, Sims J, Yaari R, Team D. Solanezumab in‐depth outcomes. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038028.Peer-Reviewed Original ResearchSporadic Alzheimer's diseaseDelayed Recall scoresAlzheimer's diseaseDisease progressionDouble-blind placebo-controlled trialLate-onset sporadic Alzheimer's diseaseTotal scoreLow-dose trialPlacebo-controlled trialAnti-amyloid therapiesOnset of symptomsPrimary cognitive outcome measureΒ-amyloid proteinInternational Shopping List TestMMSE total scoreDisease progression modelPrimary endpointSecondary outcomesSymptomatic patientsDose trialControl subjectsCSF markersClinical trialsCognitive outcome measuresEarly initiation
2009
123I-5-IA-85380 SPECT Imaging of Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment
Mitsis EM, Reech KM, Bois F, Tamagnan GD, MacAvoy MG, Seibyl JP, Staley JK, van Dyck CH. 123I-5-IA-85380 SPECT Imaging of Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment. Journal Of Nuclear Medicine 2009, 50: 1455-1463. PMID: 19690024, DOI: 10.2967/jnumed.109.064030.Peer-Reviewed Original ResearchConceptsAdvanced Alzheimer's diseaseMild cognitive impairmentHealthy control subjectsControl subjectsCognitive impairmentAge-matched healthy control subjectsAlzheimer's diseaseBrain regionsEffect of diagnosisNicotinic acetylcholine receptorsLate-stage phenomenonCholinergic reductionIA-85380Effect of ageUnivariate analysisNicotinic receptorsAnterior cingulateConstant infusionAcetylcholine receptorsTrail Making TestMultivariate analysisNeuropsychologic variablesDiagnostic groupsSignificant overall effectSPECT imaging
2005
Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease
Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology Of Aging 2005, 27: 1416-1424. PMID: 16182410, DOI: 10.1016/j.neurobiolaging.2005.08.002.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseAD patientsAPOE epsilon4AD groupImportant genetic risk factorApolipoprotein E epsilon4Regional brain atrophyAPOE epsilon4 alleleElderly control subjectsNormal elderly control subjectsGenetic risk factorsAmygdaloid volumesBrain atrophyControl subjectsEpsilon4 carriersRisk factorsEpsilon4 alleleHippocampal volumeEpsilon4 doseAnalysis of covarianceDisease severityPatientsEpsilon4AmygdalaAtrophy
2000
Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT
van Dyck C, Malison R, Seibyl J, Laruelle M, Klumpp H, Zoghbi S, Baldwin R, Innis R. Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT. Neurobiology Of Aging 2000, 21: 497-501. PMID: 10924762, DOI: 10.1016/s0197-4580(00)00152-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAgingBrain ChemistryBrain StemCarrier ProteinsCocaineDiencephalonFemaleHumansIodine RadioisotopesMaleMembrane GlycoproteinsMembrane Transport ProteinsMiddle AgedNerve Tissue ProteinsReference ValuesSerotonin Plasma Membrane Transport ProteinsTomography, Emission-Computed, Single-PhotonConceptsSERT availabilitySerotonin transporterCentral serotonin transporter availabilityHealthy control subjectsSerotonin transporter availabilitySignificant inverse correlationCentral serotonin transportersAge range 18Single photon emissionBeta-carbomethoxy-3 betaEffect of ageAge-related declineBrain uptakeCIT SPECTControl subjectsPostmortem studiesTransporter availabilityHuman brainstemLinear regression analysisInverse correlationAgeHuman subjectsRegression analysisPhoton emissionPresent studyDopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT
Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D’Souza D, Krystal J, Seibyl J, Baldwin R, Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT. Biological Psychiatry 2000, 47: 371-379. PMID: 10704949, DOI: 10.1016/s0006-3223(99)00257-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBrain StemCarrier ProteinsCase-Control StudiesCocaineDopamineDopamine Plasma Membrane Transport ProteinsFemaleHumansIodine RadioisotopesMaleMembrane GlycoproteinsMembrane Transport ProteinsMiddle AgedNeostriatumNerve Tissue ProteinsSchizophreniaSerotoninSerotonin Plasma Membrane Transport ProteinsTomography, Emission-Computed, Single-PhotonConceptsAmphetamine-induced dopamine releaseStriatal dopamine transporterDopamine transporterControl subjectsDAT densityDopamine releaseNegative symptomsStriatal DAT densityDuration of illnessDopamine nerve terminalsHealthy control subjectsSerotonin transporter densityCohort of subjectsRelative deficitSingle photon emissionNeurodegenerative processesPostmortem studiesNerve terminalsSerotonin functionTrend-level associationReceptor radiotracerPatientsDopamine functionLower striatalTransporter density
1999
[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia
Verhoeff N, Soares J, D’Souza C, Gil R, Degen K, Abi-Dargham A, Zoghbi S, Fujita M, Rajeevan N, Seibyl J, Krystal J, van Dyck C, Charney D, Innis R. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research 1999, 91: 163-173. PMID: 10641580, DOI: 10.1016/s0925-4927(99)00027-x.Peer-Reviewed Original ResearchConceptsDuration of illnessHealthy control subjectsControl subjectsGamma-aminobutyric acidLeft precentral gyrusSuperior occipital gyrusPANSS scoresPrecentral gyrusOccipital gyrusSignificant differencesTotal brain uptakeNon-smoking patientsGray matter atrophyConstant infusion paradigmPathophysiology of schizophreniaCortical brain regionsSingle photon emissionTypical antipsychoticsAtypical antipsychoticsCigarette smokingInhibitory neurotransmissionBrain uptakeInfusion paradigmMatter atrophyPostmortem studies